Neuropharmacology
December 2018
Christine A Rabinak, Craig A Peters, Hilary A Marusak et al.
We have previously demonstrated that an acute dose of Δ9-tetrahydrocanninbinol (THC), administered prior to extinction learning, facilitates later recall of extinction learning and modulates the underlying neural circuitry, including the ventromedial prefrontal cortex (vmPFC), hippocampus (HPC), and amygdala (AMYG). It remains unknown whether THC-induced changes in fear-extinction neural...
Psychological Medicine
December 2018
Subhadip Paul, Sagnik Bhattacharyya
Although alterations in medial temporal lobe structures have been previously associated with use of cannabis, one of the most widely used illicit drugs, whether such alterations are a cause or effect of cannabis use has been unclear. In this cross-sectional observational study involving 404 twins/siblings, we have compared cortical thickness and surface area between groups of gender-matched...
Experimental and Clinical Psychopharmacology
December 2018
Marco Colizzi, Philip Mcguire, Vincent Giampietro et al.
Cannabis can induce transient psychotic and anxiety symptoms and long-lasting disorders. The acute psychoactive effects of its main active ingredient, (-)-trans-Δ9-tetrahydrocannabinol (Δ9-THC), may be modulated by previous cannabis exposure. Secondary data analyses tested whether modest previous cannabis exposure modulated the acute effects of Δ9-THC on attentional salience and emotional...
Journal of Psychopharmacology
December 2018
Douglas L Boggs, Jose A Cortes-Briones, Toral Surti et al.
Binding studies have demonstrated that levels of the cannabinoid receptor type-1 are highest in the basal ganglia and cerebellum, two areas critical for motor control. However, no studies have systematically examined the dose-related effects of intravenous delta-9-tetrahydrocannabinol, the primary cannabinoid receptor type-1 partial agonist in cannabis, on broad domains of psychomotor function...
Neuropsychopharmacology
November 27, 2018
Hanna J Szkudlarek, Sagar Desai, Justine Renard et al.
63 citations
The use of cannabis for therapeutic and recreational purposes is growing exponentially. Nevertheless, substantial questions remain concerning the potential cognitive and affective side-effects associated with cannabis exposure. In particular, the effects of specific marijuana-derived phytocannabinoids on neural regions such as the prefrontal cortex (PFC) are of concern, given the role of the...
Addiction
November 16, 2018
B. Leadbeater, Megan E. Ames, A. Linden-Carmichael
Abstract Aims We tested the age‐varying associations of cannabis use (CU) frequency and disorder (CUD) with psychotic, depressive and anxiety symptoms in adolescent and adult samples. Moderating effects of early onset (≤ 15 years) and sex were tested. Design Time‐varying effect models were used to assess the significance of concurrent associations between CU and CUD and symptoms of psychosis,...
Biochemical Pharmacology
November 2018
V Salgado-Mendialdúa, J Aguirre-Plans, E Guney et al.
Cannabis is the most consumed illicit drug worldwide. Its principal psychoactive component, Δ9-tetrahydrocannabinol (THC), affects multiple brain functions, including cognitive performance, by modulating cannabinoid type-1 (CB1) receptors. These receptors are strongly enriched in presynaptic terminals, where they modulate neurotransmitter release. We analyzed, through a proteomic screening of...
The International Journal of Neuropsychopharmacology
November 1, 2018
Bruna Cuccurazzu, Erica Zamberletti, Cristiano Nazzaro et al.
In rodent models, chronic exposure to cannabis' psychoactive ingredient, Δ9-tetrahydrocannabinol, during adolescence leads to abnormal behavior in adulthood. In female rats, this maladaptive behavior is characterized by endophenotypes for depressive-like and psychotic-like disorders as well as cognitive deficits. We recently reported that most depressive-like behaviors triggered by adolescent...
International Journal of Social Psychiatry
November 1, 2018
M. B. Ortiz-Medina, M. Perea, Julio Torales et al.
Objective: Cannabis consumption produces psychopathology, in some cases psychotic episodes, which are of our interest in this work. However, the relationship between cannabis use and psychosis has not been fully elucidated. The objectives of this work are to (1) review the current state of knowledge on the association of cannabis use with the risk of the development of psychosis or psychotic...
Frontiers in Neuroscience
October 23, 2018
Libor Uttl, Ewa Szczurowska, Kateřina Hájková et al.
24 citations
Synthetic cannabinoid compounds are marketed as ‘legal’ marijuana substitutes, even though little is known about their behavioral effects in relation to their pharmacokinetic profiles. Therefore, in the present study we investigated the behavioral effects of systemic treatment with the two synthetic cannabinoids JWH-073 and JWH-210 and the phytocannabinoid Δ9-THC on locomotor activity and...